HLA
LRMR icon

Hamilton Lane Advisors’s Larimar Therapeutics LRMR Stock Holding History

Hamilton Lane Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-10,412
Closed -$3.99M – 55
2015
Q3 		$3.99M Buy
10,412
+5,847
+128% +$2.64M 1.97% 14
2015
Q2 		$1.9M Sell
4,565
-1,680
-27% -$703K 0.72% 30
2015
Q1 		$2.97M Buy
+6,245
New +$2.96M 1.35% 15

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Hamilton Lane Advisors's LRMR Position: Q4 2015 in Review

Hamilton Lane Advisors sold out of Larimar Therapeutics (LRMR) in Q4 2015, closing a stake of 10,412 shares — an estimated $3.99M sold.

Hamilton Lane Advisors first reported a position in LRMR in Q1 2015 and held it in 3 quarters. The position peaked at $3.99M in Q3 2015. 87 funds tracked by Wall St. Rank hold LRMR as of Q4 2015.

  • Hamilton Lane Advisors reported no remaining Larimar Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Hamilton Lane Advisors sold 10,412 Larimar Therapeutics shares in Q4 2015, an estimated $3.99M.
  • Hamilton Lane Advisors first reported a position in Larimar Therapeutics in Q1 2015 and held it in 3 quarters.
  • Hamilton Lane Advisors's Larimar Therapeutics position peaked at $3.99M in Q3 2015.
  • 87 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2015.

Based on Hamilton Lane Advisors's 13F filing for Q4 2015, filed 22 Jan 2016.